(NewsDirect)
Faron Pharmaceuticals Limited (AIM:FARN)chief executive Dr Markku Jalkanen joins Proactive's StephenGunnion with additional positive data from the Phase 1 study of theongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 forhigher-risk (HR) myelodysplastic syndrome (MDS) patients failed onprevious hypomethylating agent (HMA).
Dr Jalkanen said the study demonstrated promising results inreducing cancer cells and extending life expectancy in patients. Hehighlighted the durability and effectiveness of the treatment,particularly in patients with a severe form of myeloid leukemia calledMDS, where current treatment options are limited.
Dr Jalkanen said the Phase 1 resultsshowed a high overall response rate and an extended overall survivalrate among patients, which could lead to a new treatment option for anunderserved patient population. He emphasized the importance ofcontinuing the study and engaging with regulators to bring thetreatment to market as swiftly as possible. He also noted thepotential for increased interest from other pharmaceutical companiesbased on the positive data released.
Faron Pharmaceuticals hasmoved to the Phase 2 part of the study, focusing on finalising dosingand drug levels as per FDA guidance. The goal is to establish a clearpathway to market approval.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.